PRIMARY STUDY
Renovascular protective effects of erythropoietin in patients with chronic kidney disease
Key Findings: Treatment with erythropoietin (EPO) in patients with chronic kidney disease (CKD) significantly improved serum hemoglobin levels, and decreased inflammatory biomarks including urinary protein, L-FABP and 8-OHdG, carotid IMT, baPWV, plasma BNP and serum ADMA.
Type of Study: Clinical Trial
Study Sample Size: 15
Study Result: Positive
Study Location(s): Japan
Year of Pub: 2011
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
